hypothyroidism and semaglutide Semaglutide-induced Subclinical Hypothyroidism: A Case Report Combined Treatment of Type 2

Approval status 2026 Timeline for FDA, EMA and BfArM plus details on the TRIUMPH-1 trial

Some might discontinue with close medical supervision

Body weight influences needslarger individuals generally require more fluid, though personalized targets should be developed with healthcare providers

This model eliminates the inventory delays and regional shortages that have affected branded alternatives, ensuring consistent availability for patients seeking treatment

Interviews were recorded, transcribed, and analyzed using ATLAS.ti

By end user, the retail pharmacies segment held the dominating share of 51% in the market in 2025